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Abstract
Lung macrophages may play a relevant role in oxidative processes producing both superoxide anion ðO2 Þ and NO. In this view,
an antioxidant therapy can be useful in the treatment of systemic sclerosis (SSc) patients. N-Acetylcysteine (NAC) is able to expand
natural antioxidant defenses by increasing intracellular gluthatione concentration and it has been proposed as an antioxidant
therapy in respiratory distress syndromes. The aim of our study was to determine whether lung macrophages obtained from SSc
patient bronchoalveolar lavage (BAL) express the inducible form of nitric oxide synthase (iNOS) and whether NAC can reduce the
peroxynitrite ðONOOÞ and O2 production of these cells. Alveolar macrophages were isolated from BAL of 32 patients and used
for the immunocytochemical determination of iNOS, and the production of ONOO and O2 was measured by fluorimetric or
spectrophotometric methods, respectively. Lung macrophages obtained from SSc patients expressed a higher level of iNOS com-
pared to healthy subject cells. NAC preincubation (5 105 M, 24 h) significantly reduced ()21%) the ONOO production in
formyl Met-Leu-Phe (fMLP)-activated cells and slightly reduced it under resting conditions, whereas NAC preincubation was
unable to modify the release of O2 both in basal condition and in fMLP-stimulated cells. We conclude that since SSc lung
macrophages express high levels of iNOS and produce a significant quantity of ONOO, NAC administration reduces ONOO
production and can be an useful treatment to alleviate SSc symptoms.
 2002 Elsevier Science (USA). All rights reserved.
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Nitric oxide (NO)1 is physiologically produced by
constitutive nitric oxide synthase isoforms (cNOS) and in
several pathophysiological conditions by an inducible
nitric oxide synthase isoform (iNOS). In systemic scle-
rosis (SSc) patients, NO is increased in exhaled air [1,2]
while it is decreased in those patients with pulmonary
hypertension [2,3]. Moreover, serum NO levels are en-
hanced [4], iNOS is highly expressed in mononuclear
cells infiltrating the skin [4] and peripheral blood
mononuclear cells produce increased NO levels when
stimulated with IL-1  [5]. NO can be synthesized by
different kinds of cells. Among these cells, macrophages
play a pivotal role in the inflammatory infiltrate and, in
patients with tubercolosis, iNOS is expressed in alveolar
macrophages [6]. Inflammatory cells produce reactive
oxygen species (ROS) that, reacting with NO, form tis-
sue-damaging NO-derived inflammatory oxidants. ROS
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are considered toxic for many tissues. Among ROS, NO-
derived oxidant species such as peroxynitrite [7] and
hypochlorous derivatives [8] possess strong damaging
properties responsible for epithelial shedding, airway
hypereactivity, nerve sensitization, plasma exudation,
and tyrosine nitrosylation [9]. In SSc, a ROS involve-
ment in the disease pathogenesis has been suggested
[10,11]. Indeed, in SSc the increased serum levels of an-
tibodies against oxidized low-density lipoproteins reveal
a generalized oxidative stress [12] and peripheral blood
monocytes obtained from SSc produce a large amount of
O2 anion [13] and NO [5,14]. In vitro, ONOO
 pro-
duction induced by combined hyperoxia and NO is
cytotoxic on human alveolar epithelial and lung micro-
vascular endothelial cells [15] and the expression of both
nitrotyrosine and iNOS as a marker of ONOO pro-
duction is increased in lung macrophages, neutrophils,
and alveolar epithelial cells of patients with idiopathic
pulmonary fibrosis compared to healthy subjects [16].
Therefore, the toxicity of NO-derived oxidant species
might be responsible for the inflammatory lung damage
observed in SSc patients. Lung macrophages may pro-
duce both O2 anion and NO that can react together to
form ONOO. In this view, an antioxidant therapy can
be useful in the treatment of SSc patients [17]. N-Acet-
ylcysteine (NAC) is able to expand natural antioxidant
defense by increasing intracellular reduced gluthatione
(GSH) concentration [18,19] and it has been proposed as
an antioxidant therapy in respiratory distress syndromes
[20]. Effectiveness of NAC in reducing the exacerbation
of severe chronic obstructive pulmonary disease has been
documented [21] and, more recently, in SSc, NAC in-
travenous administration has been shown to reduce sig-
nificantly the number of Raynaud’s phenomenon attacks
[22]. In an early report, the effect of NAC (administered
for 5 days) on the O2 anion production of rat alveolar
macrophages and human peripheral neutrophiles was
evaluated [23]. However, although the in vivo NAC
treatment increases the GSH level both in human plasma
and in rat bronchoalveolar lavage (BAL), the NAC
effectiveness is poor in scavenging O2 anion [23].
According to recent data, NAC can prevent peroxyni-
trite-mediated oxidation in a model of ischemia–reper-
fusion in the rat [24] and directly reduces ONOO
formation in rat macrophages obtained from the pleural
cavity in a model of carrageenan-induced pleurisy [25].
Moreover, in an acute model of renal failure produced by
inferior vena cava occlusion the protective effect of NAC
is dependent on the scavenging of ONOO and is
observed only when NO is physiologically produced,
since the NG-nitro-L-arginine methyl ester NOS inhibitor
abolishes it [26]. Therefore, the aim of our study was to
determine the iNOS expression and the effectiveness of
NAC treatment in the reduction of the ONOO and O2
anion production in lung alveolar macrophages obtained
from BAL of SSc patients.
Methods
Patients
Lung alveolar macrophages were obtained from 27
female and 5 male patients (mean age 50:5 0:6 years)
affected by SSc (12 patients with cutaneous diffuse SSc
and 20 with cutaneous limited SSc) with an impairment
of the lung diffusion of CO (Dlco) at pulmonary func-
tion tests, an increased velocity of 99mTc DTPA pul-
monary clearance rate at the alveolar membrane [27],
and ground glass without reticular pattern at chest high-
resolution computed tomography [28] demonstrating a
lung involvement. These patients were chosen since they
were considered to be in an early phase of the disease
and pulmonary fibrosis was not evident. Cardiac echo-
colordoppler excluded the presence of pulmonary hy-
pertension. All patients underwent BAL as a procedure
for determining the presence of an active process of al-
veolar inflammation. According to the results of BAL
cellularity, patients analyzed for iNOS expression were
divided into BAL positive (>8% lymphocytes) or BAL
negative (<8% lymphocytes) alveolitis. Two healthy
subjects undergoing BAL for a suspected lung cancer
that was demonstrated to be negative afterward were
used as controls. Due to the paucity of macrophage cell
recovery in the BAL, experiments investigating iNOS
expression and ONOO and O2 anion production were
performed on different subjects. Immunocytochemical
determination of iNOS was performed on 11 patients (5
with cutaneous diffuse, 6 with cutaneous limited SSc),
ONOO anion measurements were performed on 10
patients (four with cutaneous diffuse SSc and 6 with
cutaneous limited SSc), and O2 anion measurements
were performed on 11 patients (three with cutaneous
diffuse SSc and eight with cutaneous limited SSc).
However, in these three groups of patients, the main
clinical characteristics and the age and sex distribution
were homogeneous.
Alveolar macrophage isolation and preparation
After premedication with atropine and anesthetics, a
bronchoscope was introduced into airways and 200ml
of sterile saline solution was injected into the lobe
affected by ground glass. From the recovered fluid,
macrophages were prepared by centrifugation at 700g
for 10min. The pellet was resuspended in RPMI 1640
medium containing antibiotics (penicillin 100U/ml
and streptomycin 0.1mg/ml) and 10% fetal calf serum
(FCS). The cell suspension was plated in Labtek
chambers at a concentration of 1 104–105 cells/well for
iNOS expression and cytocharacterization. In parallel
experiments for iNOS expression, cells of one healthy
subject and from guinea pig BAL [29] were treated
with 10lg=ml lipopolysaccharides (LPS), a known up-
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regulator of iNOS expression in macrophages. After 2 h,
unattached cells and debris were removed by washing,
media were changed, and macrophages were used 24 h
after plating as described. The macrophage cytochar-
acterization performed by staining the endogenous
peroxidase with 3,30-diaminobenzidine tetrahydrochlo-
ride–H2O2 indicated the presence of adherent macro-
phages ranging from 78% to 89%.
iNOS expression
Macrophages were washed and fixed by short im-
mersion (5min) in cold acetone. The expression of iNOS
was detected by incubating cells overnight at room
temperature with the rabbit iNOS primary polyclonal
antibody used at a 1:100 dilution in phosphate-buffered
(PBS) saline containing 0.3% Triton X-100, 2% normal
goat serum, and 0.5% bovine serum albumine (BSA).
On the following day, specimens were washed and
incubated for 1 h at room temperature with fluorescein-
conjugated (FITC-conjugated) secondary antibody
diluted 1:40 in PBS–0.5% BSA and 2% normal goat
serum. Analysis was performed by imaging analysis
system.
Fluorescence intensity (excitation 480 nm, emission
520 nm) was quantified in the single cell using an ana-
logical/digital converter recognizing 256 gray levels
(Magiscan, Applied Imaging) and Tardis software and
was expressed as arbitrary units. Negative control for
the immunostaining was obtained either by omission of
the primary antibody or by use of bNOS as the primary
antibody. The fluorescence of negative controls was
subtracted by immunostained specimens as background
fluorescence level. However, the negative control fluo-
rescence was negligible as compared to that of the
specimens (less than 1/10th). Thirty to thirty-five cells
showing the typical round aspect of macrophages from
subjects were analyzed and the fluorescence intensity for
each subject was calculated as the mean of analysed
cells. LPS-treated macrophages showed a significant
increase in fluorescence ðp < 0:001Þ of 1.6- and 1.5-fold
compared to unstimulated human and guinea pig cells,
respectively. In several experiments, 10lM dexametha-
sone was added soon after centrifugation and main-
tained during the 24-h incubation. No significant
differences in iNOS immunostaining were detected in
cells incubated either in the absence or in the presence of
dexamethasone, ruling out the possibility that iNOS
expression may be induced during the 24-h incubation
time.
Peroxynitrite anion assay
Macrophages were plated in six multiwell plates
(106 cells/well) and washed after 2 h. Adherent macro-
phages were allowed to stay in the absence (control) or
presence of 5 105M NAC for 24 h. ONOO pro-
duction was evaluated by fluorimetric measure of oxi-
dized dihydrorhodamine-123 [30] after a 60-min
incubation of 106 macrophages under resting conditions
and after stimulation with 108 M fMLP in the presence
or absence of 5 105M NAC. A blank specimen was
obtained by carrying out a contemporaneous determi-
nation in the presence of either superoxide dismutase
(SOD) (to quench O2 anion) or 1400W, an inhibitor of
iNOS [31]. No significant differences between fluorimet-
ric measures obtained in the presence of 1400W and
SODwere observed. Therefore, this value was subtracted
as an aspecific reaction of dihydrorhodamine-123.
Nitrite assay
To test whether NAC can interfere with NO produc-
tion, nitrite concentration wasmeasured using a standard
Griess micromethodology as described [32]. Guinea pig
lungmacrophages were used for this test as described [29].
Cells were plated in six multiwell plates (106 cells/well) in
phenol red-free RPMI 1640 medium with a composition
similar to that above in the presence or absence of
5 105M NAC, and nitrite production was measured
after 24-h incubation on cell supernatant. In parallel ex-
periments, cells were treated with 10lg=ml LPS in the
presence or absence of 5 105 M NAC for 24 h and
washed, and nitrite productionwas assessed under resting
conditions and after stimulationwith 108M fMLP in the
presence or absence of 5 105M NAC.
Superoxide anion assay
Macrophages were plated in six multiwell plates
(106 cells/well) as described (see peroxynitrite anion as-
say). O2 production was evaluated by SOD-inhibitable
reduction of ferricytochrome c [28] after a 60-min in-
cubation of 106 macrophages under resting conditions
and after stimulation with 108M fMLP in the presence
or absence of 5 105M NAC in phosphate-buffered
saline. To evaluate fMLP-induced O2 production, val-
ues obtained under resting conditions under different
treatments were subtracted.
Statistical methods
Values are presented as means SE of analyzed
subjects. Statistical comparisons between data groups
were performed using Student’s t test (paired and
independent). A p < 0:05 was considered statistically
significant.
Materials
fMLP, penicillin–streptomycin (antibiotic solution),
SOD, NAC, dihydrorhodamine-123, secondary anti-rabbit
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FITC conjugate monoclonal antibodies, and ferricyto-
chrome c were purchased from Sigma–Aldrich s.r.l.
(Milan, Italy); RPMI 1640 medium and FCS were ob-
tained from Gibco BRL-Life Technologies (Milan, Italy)
and 1400W, iNOS, and bNOS from Calbiochem (La
Jolla, CA). Cell culture plastic supports were purchased
from Costar (Corning Costar Co., Costar Italia, Milan,
Italy). All other reagents were of analytical grade.
Results
All the SSc patients showed a ground glass appear-
ance at high-resolution computed tomography of the
lung without reticular pattern. The BAL cellularity,
performed in the affected lobe, identified two groups of
patients, one with an increased number of lymphocytes
(BAL positive) and the other with a normal number of
lymphocytes (BAL negative).
In both groups, all macrophages immunostained with
the primary antibody showed a detectable level of flu-
orescence for iNOS. No difference was found in the two
groups, the group with a positive BAL being insignifi-
cantly higher than that with a negative BAL. However,
as shown in Fig. 1, lung macrophages obtained from SSc
patients expressed a higher level of iNOS than those
from healthy subjects.
No correlations between iNOS expression and lym-
phocytes or other bronchoscopic and clinical parameters
were found.
Since the iNOS expression was high in patient lung
macrophages, we investigated the cell production of
ONOO and O2 anions and the effect of NAC on these
levels. As shown in Figs. 2A and B the basal production
of ONOO and O2 anions was significantly increased
after stimulation with 108M fMLP, a dose that, ac-
cording to preliminary data obtained in alveolar lung
human macrophages and our previous works on guinea
pig lung macrophages [29], was maximal. The ONOO
and O2 anion levels in both groups of patients did not
correlate with lymphocytosis or other bronchoscopic
and clinical parameters. NAC preincubation ð5 
105MÞ significantly reduced the ONOO production in
fMLP-activated cells and slightly reduced it under rest-
ing conditions (Fig. 2A). An NAC inhibitory effect was
observed only when NAC preincubation lasted over-
night, while 1-h preincubation was ineffective. On the
other hand, 5 105M NAC preincubation was unable
to modify the release of O2 anion, both under resting
conditions and in fMLP-stimulated cells, although
in fMLP-stimulated cells NAC slightly decreased it
(Fig. 2B).
To test whether NAC can directly interfere with NO
production, we measured nitrite production of guinea
pig macrophages. The preincubation with 5 105M
NAC reduced nitrite production in the 24-h cell super-
natant from 4:5 0:56lM (control) to 1:2 0:22lM
(NAC, p < 0:001, paired Student’s t test, n¼ 4). More-
over, NAC reduced nitrite production from
4:9 0:73lM (control) to 3:6 0:49lM (NAC,
p < 0:05, paired Student’s t test, n¼ 4) in fMLP-stimu-
lated LPS-pretreated guinea pig lung macrophages,
whereas NAC was unable to reduce nitrite production in
LPS-pretreated unstimulated cells (4:1 0:58lM con-
trol vs 3:3 0:39lM NAC, n¼ 4).
Discussion
Our data clearly demonstrate that SSc lung macro-
phages express high levels of iNOS and produce a
Fig. 1. iNOS expression in lung macrophages obtained by bronc-
hoalveolar lavage from SSc patients with (BAL Positive, n¼ 5) or
without (BAL Negative, n¼ 6) alveolitis and healthy subjects (n¼ 2).
Each point represents the immunostaining fluorescence mean of 30–35
cells from the same specimen quantified by imaging analysis. Bars are
the mean of each groups. Vertical scale: fluorescence, arbitrary units.
Fig. 2. Effect of NAC (5 105M, 24 h) on the release of peroxynitrite
(ONOO, A) and superoxide anion (O2 , B) in lung macrophages
obtained by bronchoalveolar lavage from SSc patients. Values are the
mean (SE) of the indicated number of experiments; p < 0:05.
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significant quantity of ONOO and O2 anions. How-
ever, since no correlation among lung inflammatory
parameters and iNOS expression has been found, the
higher iNOS expression in SSc might be considered an
early but aspecific pathological sign suggesting that
previous lung inflammation (ground glass without in-
creased cellularity) or current lung inflammation
(ground glass with increased cellularity), priming mac-
rophages for iNOS expression, may be an aspecific event
secondary to the process of systemic inflammation. The
up-regulation of iNOS in macrophages might contribute
to the increased levels of exhaled NO [1,2]. Our data also
demonstrate that alveolar macrophages are not func-
tionally impaired since fMLP can increase both
ONOO and O2 anion production. The NO production
together with the concomitant release of O2 anion and
hypochlorous acid may determine high local concen-
trations of reactive NO-derived, very potent inflamma-
tory oxidants. This process can greatly contribute to
the inflammatory process and enhance tissue damage
leading to alveolar injury.
The data obtained with NAC preincubation are in
agreement with the work previously performed by
Sambo et al. [13] on SSc circulating monocytes. In our
work,NAC preincubation reduces ONOO anion release
without affecting O2 anion production after an in vitro
overnight treatment of SSc macrophages. These data are
in agreement with early reports showing similar NAC
effects on different cell types [23–25] and in vivo [26].
According to the current literature, NAC can exert its
beneficial action on inflammation and inflammatory-
linked tissue damage through several mechanisms. In
our in vitro experiments it seems likely that NAC can
reduce ONOO formation by reducing nitrite produc-
tion, since in experiments performed on guinea pig lung
macrophages, NAC can directly reduce nitrite forma-
tion. This effect may be dependent on a direct reaction
of NAC thiol group and NO, thus producing a ni-
trothiol compound. The formation of these nitrothiol
compounds can preserve and accumulate NO in a bio-
logically active form. A similar mechanism could explain
the NAC protective effect described by Conesa and co-
authors in their acute renal failure in vivo model [26] in
which the presence of NO is essential for attempting
NAC beneficial effect. On the other hand, NAC is un-
able to modify the O2 production, ruling out a scav-
enging effect on this ROS. Moreover, no significant
differences between iNOS expression levels have been
detected during the incubation time in the control
condition, ruling out a possible NAC effect on iNOS
induction.
Although we have tested the in vitro NAC effect, it is
probable also that in vivo NAC therapeutical adminis-
tration may reduce ONOO formation by alveolar
macrophages, not only in SSc patients, but also in other
pulmonary pathologies.
Therefore, NAC by its reducing effect on ONOO
might become a useful antioxidant therapy not only by
systemic infusion [22] but also by aerosol delivery in
pulmonary airways, synergizing other therapies in the
treatment of SSc patients.
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